StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
144
This month
1
This year
12
Publishing Date
2024 - 02 - 19
2
2023 - 10 - 23
2
2023 - 09 - 11
3
2022 - 12 - 07
2
2022 - 10 - 27
2
2022 - 08 - 15
2
2022 - 08 - 12
2
2022 - 07 - 25
2
2022 - 06 - 27
2
2022 - 06 - 03
3
2022 - 05 - 05
2
2022 - 04 - 13
1
2022 - 04 - 08
1
2022 - 04 - 06
1
2022 - 04 - 05
1
2022 - 04 - 04
1
2022 - 04 - 02
1
2022 - 03 - 30
1
2022 - 03 - 23
1
2022 - 03 - 08
1
2022 - 03 - 07
1
2022 - 03 - 02
1
2022 - 03 - 01
1
2022 - 02 - 23
1
2022 - 02 - 21
1
2022 - 01 - 17
1
2022 - 01 - 14
1
2022 - 01 - 13
1
2022 - 01 - 05
1
2022 - 01 - 03
1
2021 - 12 - 23
1
2021 - 12 - 14
1
2021 - 12 - 09
1
2021 - 11 - 30
1
2021 - 11 - 24
1
2021 - 11 - 18
1
2021 - 11 - 03
2
2021 - 10 - 25
1
2021 - 10 - 06
1
2021 - 09 - 17
1
2021 - 09 - 13
1
2021 - 09 - 08
1
2021 - 09 - 07
1
2021 - 08 - 23
1
2021 - 08 - 05
2
2021 - 07 - 28
1
2021 - 07 - 27
1
2021 - 07 - 12
1
2021 - 06 - 22
1
2021 - 06 - 17
1
2021 - 06 - 08
1
2021 - 05 - 24
1
2021 - 05 - 05
1
2021 - 05 - 04
1
2021 - 04 - 20
1
2021 - 04 - 12
1
2021 - 04 - 09
1
2021 - 03 - 18
1
2021 - 03 - 16
1
2021 - 01 - 11
1
Sector
Electronic technology
1
Health services
3
Health technology
144
Manufacturing
7
N/a
1
Professional, scientific, and technical services
5
Technology services
2
Tags
Agreement
11
Alliances
24
America
28
Antibody
19
Astrazeneca
15
Biotech
28
Breast
11
Breast cancer
13
Cancer
144
Cell
14
Clinical-trials-phase-iii
16
Collaboration
14
Covid-19
8
Diabetes
16
Diagnostic
10
Diagnostics
11
Disease
34
Drug
70
Drug delivery
12
Enhertu
24
Europe
11
Expected
13
Fda
9
Financial
10
Financial results
9
Global
108
Granted
8
Growing
24
Growth
120
Health
9
Her2
27
Her2-
18
Immunotherapy
10
Iot
8
Key
9
License
16
Liver
18
Lung
24
Lung cancer
10
Market
267
Metastatic breast cancer
11
N/a
516
Partnership
8
People
10
Pharma
10
Positive
13
Reach
20
Report
95
Research
73
Respiratory
12
Results
30
Review
11
Set
16
System
9
Technology
10
Therapeutics
71
Therapy
32
Treatment
46
Trial
52
Vaccine
29
Entities
Abbott laboratories
5
Abbvie inc.
14
Accuray incorporated
1
Adaptimmune therapeutics plc
3
Adobe inc.
1
Advaxis, inc.
1
Agenus inc.
1
Agilent technologies, inc.
1
Alphabet inc.
2
Amgen inc.
28
Artelo biosciences, inc.
2
Astellas pharma inc
7
Astrazeneca plc
144
Aveo pharmaceuticals, inc.
4
Baxter international inc.
3
Becton, dickinson and company
1
Biogen inc.
3
Biontech se
2
Blueprint medicines corporation
1
Bristol-myers squibb company
19
Cel-sci corporation
1
Clovis oncology, inc.
2
Compugen ltd.
2
Crinetics pharmaceuticals, inc.
2
Cts corporation
1
Curevac n.v.
1
Eli lilly and company
24
Endo international plc
1
Exact sciences corporation
1
Exelixis, inc.
2
Fortress biotech, inc.
1
Fresenius medical care ag & co. kgaa
1
Fusion pharmaceuticals inc.
1
Genelux corp
1
Genprex, inc.
9
Gilead sciences, inc.
1
Glaxosmithkline plc
28
Hologic, inc.
1
Hutchison china meditech limited
5
Illumina, inc.
5
Incyte corporation
2
Innate pharma s.a.
2
Innate pharma sa
2
Invitae corporation
1
Jazz pharmaceuticals plc
4
Johnson & johnson
8
Koninklijke philips n.v.
1
Kura oncology, inc.
1
Macrogenics, inc.
1
Novartis ag
36
Novo nordisk a/s
3
Oncolytics biotech inc.
3
Pfizer, inc.
10
Puma biotechnology inc
3
Q biomed inc.
4
Sanofi
28
Takeda pharmaceutical company limited
8
Teva pharmaceutical industries ltd
9
Ucb s.a.
2
Viatris inc.
5
Symbols
A
27
ABBV
53
ABT
48
ALPMF
49
ALPMY
49
AMGN
91
ANIX
49
ARAY
26
AVEO
24
AZN
144
AZNCF
74
BCTX
50
BDX
26
BGNE
59
BIOC
31
BMY
107
BPMC
27
CLVS
33
CSTL
28
EXAS
56
EXEL
43
FNCTF
138
GH
54
GILD
59
GLAXF
46
GNPX
26
GSK
54
GTHX
27
HOLX
32
HOTH
29
IBRX
30
ILMN
68
IMGN
25
IMMP
34
INCY
57
JAGX
37
JNJ
138
KPTI
27
LLY
139
LTRN
25
MRK
75
MRTX
32
MYGN
50
NTRA
38
NVCR
30
NVS
106
NVSEF
91
NVTA
25
ONCY
41
PDSB
35
PFE
66
QGEN
31
REGN
42
SGEN
55
SNY
216
SNYNF
166
TAK
34
TMO
51
VCYT
46
VSTM
25
Exchanges
Amex
1
Nasdaq
144
Nyse
61
Crawled Date
2024 - 02 - 19
2
2023 - 12 - 19
2
2023 - 10 - 23
2
2023 - 09 - 11
3
2022 - 12 - 07
2
2022 - 10 - 27
2
2022 - 08 - 15
2
2022 - 08 - 12
2
2022 - 07 - 25
2
2022 - 06 - 27
2
2022 - 06 - 03
3
2022 - 05 - 05
2
2022 - 04 - 13
1
2022 - 04 - 08
1
2022 - 04 - 06
1
2022 - 04 - 05
1
2022 - 04 - 04
1
2022 - 04 - 02
1
2022 - 03 - 30
1
2022 - 03 - 23
1
2022 - 03 - 08
1
2022 - 03 - 07
1
2022 - 03 - 02
1
2022 - 03 - 01
1
2022 - 02 - 23
1
2022 - 02 - 21
1
2022 - 01 - 17
1
2022 - 01 - 14
1
2022 - 01 - 13
1
2022 - 01 - 05
1
2022 - 01 - 03
1
2021 - 12 - 23
1
2021 - 12 - 14
1
2021 - 12 - 09
1
2021 - 11 - 30
1
2021 - 11 - 24
1
2021 - 11 - 18
1
2021 - 11 - 03
2
2021 - 10 - 25
1
2021 - 10 - 06
1
2021 - 09 - 17
1
2021 - 09 - 13
1
2021 - 09 - 08
1
2021 - 09 - 07
1
2021 - 08 - 23
1
2021 - 08 - 05
2
2021 - 07 - 28
2
2021 - 07 - 12
1
2021 - 06 - 22
1
2021 - 06 - 17
1
2021 - 06 - 08
1
2021 - 05 - 24
1
2021 - 05 - 05
1
2021 - 05 - 04
1
2021 - 04 - 20
1
2021 - 04 - 12
1
2021 - 04 - 09
1
2021 - 03 - 18
1
2021 - 03 - 16
1
2021 - 01 - 11
1
Crawled Time
00:00
2
01:00
5
02:00
3
03:00
4
04:00
2
04:20
4
05:00
1
06:00
3
07:00
4
08:00
6
09:00
8
10:00
3
11:00
12
12:00
8
12:20
2
12:30
2
13:00
10
13:30
1
13:37
1
14:00
8
14:20
1
14:30
2
15:00
4
15:15
1
15:20
1
16:00
8
17:00
8
18:00
4
19:00
9
20:00
3
21:00
3
22:00
5
23:00
6
Source
www.biospace.com
60
www.chi-med.com
2
www.globenewswire.com
8
www.prnewswire.com
74
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Cancer
symbols :
Azn
save search
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Published:
2024-04-02
(Crawled : 08:00)
- biospace.com/
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
3.2%
|
O:
-1.18%
H:
0.34%
C:
-0.22%
breast
her2
license
cancer
application
negative
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
Published:
2024-03-19
(Crawled : 12:00)
- biospace.com/
FUSN
|
$21.32
0.28%
0.3%
340K
|
Health Technology
|
100.38%
|
O:
96.99%
H:
1.19%
C:
1.05%
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
6.5%
|
O:
-0.38%
H:
0.46%
C:
0.4%
astrazeneca
cancer
treat
acquire
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
Published:
2024-03-18
(Crawled : 13:30)
- biospace.com/
ILMN
|
$120.25
2.4%
2.37%
2.2K
|
Health Technology
|
-5.86%
|
O:
0.51%
H:
2.49%
C:
1.37%
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
5.76%
|
O:
-0.45%
H:
0.55%
C:
-0.24%
lung
test
cancer
risk
study
Cervical Cancer Global Clinical Trials Review 2024: Clinical Trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
Published:
2024-03-01
(Crawled : 17:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
77
|
Health Technology
|
-2.32%
|
O:
0.01%
H:
0.0%
C:
-0.43%
AZNCF
|
News
|
$138.73
1.86%
-4.19%
0
|
Health Technology
|
9.56%
|
O:
0.59%
H:
2.06%
C:
2.06%
SNY
|
News
|
$47.15
1.84%
1.75%
2M
|
Health Technology
|
-3.57%
|
O:
-1.27%
H:
0.0%
C:
0.0%
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
9.3%
|
O:
0.28%
H:
0.75%
C:
0.4%
review
cancer
trials
global
trial
Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published:
2024-02-22
(Crawled : 01:00)
- prnewswire.com
GLAXF
|
News
|
$20.305
0.52%
-14.18%
0
|
Health Technology
|
-5.41%
|
O:
0.14%
H:
0.0%
C:
-0.0%
SNYNF
|
News
|
$92.7
-2.18%
77
|
Health Technology
|
-3.13%
|
O:
0.26%
H:
1.36%
C:
1.36%
AZNCF
|
News
|
$138.73
1.86%
-4.19%
0
|
Health Technology
|
9.24%
|
O:
-0.85%
H:
1.12%
C:
0.43%
NVSEF
|
News
|
$95.11
5.4%
6.88%
0
|
Health Technology
|
-6.69%
|
O:
0.92%
H:
0.0%
C:
0.0%
UCBJY
|
$64.93
0.61%
-4.38%
6.1K
|
Manufacturing
|
27.56%
|
O:
1.46%
H:
0.44%
C:
0.44%
ALPMY
|
News
|
$9.53
0.32%
-1.11%
0
|
Manufacturing
|
-14.3%
|
O:
-0.27%
H:
0.0%
C:
-1.17%
TAK
|
News
|
$13.36
0.91%
0.0%
1.5M
|
Health Technology
|
-9.36%
|
O:
-0.2%
H:
0.14%
C:
-0.48%
NVS
|
News
|
$95.12
0.81%
4.36%
160K
|
Health Technology
|
-7.6%
|
O:
-0.06%
H:
0.46%
C:
0.29%
GSK
|
News
|
$40.59
2.11%
0.1%
1.3K
|
Health Technology
|
-3.22%
|
O:
-0.69%
H:
1.42%
C:
1.22%
LLY
|
News
|
$731.33
0.69%
0.73%
12K
|
Health Technology
|
-1.95%
|
O:
2.37%
H:
1.51%
C:
0.79%
BMY
|
$49.14
0.43%
0.2%
6.4M
|
Health Technology
|
-3.48%
|
O:
-0.65%
H:
1.63%
C:
1.48%
ABBV
|
News
|
$167.89
0.89%
0.51%
3.6M
|
Health Technology
|
-4.79%
|
O:
-0.88%
H:
1.46%
C:
1.13%
SNY
|
News
|
$47.15
1.84%
1.75%
2M
|
Health Technology
|
-1.81%
|
O:
1.67%
H:
0.0%
C:
0.0%
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
7.74%
|
O:
-2.81%
H:
2.08%
C:
1.38%
AMGN
|
News
|
$271.91
1.11%
1.12%
560
|
Health Technology
|
-4.07%
|
O:
-0.35%
H:
1.15%
C:
0.96%
lung
reach
cancer
cell
diagnostics
therapy
market
9.18% CAGR growth in Cancer Biologics Market by Product (Monoclonal antibodies, Cell and gene therapy, vaccines, and others), Route Of Administration, and Geography- Global forecast to 2028
Published:
2024-02-19
(Crawled : 16:00)
- prnewswire.com
BIIB
|
$194.11
-0.14%
-0.15%
120
|
Health Technology
|
Email alert
Add to watchlist
VTRS
|
News
A
|
$11.25
-0.13%
4.1M
|
Health Technology
|
Email alert
Add to watchlist
NVSEF
|
News
|
$95.11
5.4%
6.88%
0
|
Health Technology
|
Email alert
Add to watchlist
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
Email alert
Add to watchlist
GLAXF
|
News
|
$20.305
0.52%
-14.18%
0
|
Health Technology
|
Email alert
Add to watchlist
GSK
|
News
|
$40.59
2.11%
0.1%
1.3K
|
Health Technology
|
Email alert
Add to watchlist
AZNCF
|
News
|
$138.73
1.86%
-4.19%
0
|
Health Technology
|
Email alert
Add to watchlist
JAZZ
|
$108.83
-1.01%
-1.04%
1
|
Health Technology
|
Email alert
Add to watchlist
NVS
|
News
|
$95.12
0.81%
4.36%
160K
|
Health Technology
|
Email alert
Add to watchlist
AMGN
|
News
|
$271.91
1.11%
1.12%
560
|
Health Technology
|
Email alert
Add to watchlist
cancer
cell
global
growth
market
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Published:
2024-02-19
(Crawled : 09:00)
- biospace.com/
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
Email alert
Add to watchlist
lung
license
cancer
cell
application
advanced
Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published:
2024-02-06
(Crawled : 00:00)
- prnewswire.com
ALPMF
|
News
|
$9.75
6.33%
43.47%
0
|
Health Technology
|
-12.32%
|
O:
-1.53%
H:
0.0%
C:
0.0%
AZNCF
|
News
|
$138.73
1.86%
-4.19%
0
|
Health Technology
|
3.65%
|
O:
-0.37%
H:
0.0%
C:
0.0%
NVSEF
|
News
|
$95.11
5.4%
6.88%
0
|
Health Technology
|
-7.55%
|
O:
0.41%
H:
0.0%
C:
0.0%
UCBJY
|
$64.93
0.61%
-4.38%
6.1K
|
Manufacturing
|
38.86%
|
O:
1.71%
H:
1.28%
C:
0.94%
ALPMY
|
News
|
$9.53
0.32%
-1.11%
0
|
Manufacturing
|
-12.49%
|
O:
0.28%
H:
0.18%
C:
0.0%
TAK
|
News
|
$13.36
0.91%
0.0%
1.5M
|
Health Technology
|
-5.65%
|
O:
0.07%
H:
0.42%
C:
0.07%
NVS
|
News
|
$95.12
0.81%
4.36%
160K
|
Health Technology
|
-8.65%
|
O:
0.09%
H:
0.39%
C:
-0.36%
JNJ
|
News
|
$149.12
0.82%
0.59%
440K
|
Health Technology
|
-4.25%
|
O:
1.47%
H:
0.0%
C:
0.0%
LLY
|
News
|
$731.33
0.69%
0.73%
12K
|
Health Technology
|
3.73%
|
O:
0.76%
H:
4.31%
C:
2.11%
BMY
|
$49.14
0.43%
0.2%
6.4M
|
Health Technology
|
-0.24%
|
O:
-0.14%
H:
0.35%
C:
-1.12%
ABBV
|
News
|
$167.89
0.89%
0.51%
3.6M
|
Health Technology
|
-1.83%
|
O:
1.48%
H:
0.0%
C:
0.0%
VRTX
|
$399.92
1.43%
1.45%
1.1M
|
Health Technology
|
-4.46%
|
O:
0.15%
H:
2.4%
C:
0.56%
SNY
|
News
|
$47.15
1.84%
1.75%
2M
|
Health Technology
|
-0.55%
|
O:
1.33%
H:
0.0%
C:
0.0%
JAZZ
|
$108.83
-1.01%
-1.04%
1
|
Health Technology
|
-12.73%
|
O:
-0.02%
H:
0.0%
C:
-1.4%
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
4.61%
|
O:
-0.4%
H:
0.19%
C:
-0.33%
AMGN
|
News
|
$271.91
1.11%
1.12%
560
|
Health Technology
|
-13.97%
|
O:
-0.18%
H:
0.0%
C:
-6.22%
report
cancer
blood
growth
market
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published:
2024-02-05
(Crawled : 12:30)
- prnewswire.com
AZNCF
|
News
|
$138.73
1.86%
-4.19%
0
|
Health Technology
|
5.18%
|
O:
-0.17%
H:
0.09%
C:
-2.76%
GNPX
|
$2.163
1.55%
0.93%
600
|
Health Technology
|
-63.45%
|
O:
33.84%
H:
1.01%
C:
-15.3%
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
6.84%
|
O:
-0.76%
H:
0.77%
C:
0.0%
reqorsa
first
lung
cancer
treat
cell
expansion
therapy
study
Breast Cancer Therapeutics Market 2023, USD 15.64 billion Growth is Expected between 2023 to 2028, Robust pipeline and new drug approvals to Boost Growth - Technavio
Published:
2024-01-30
(Crawled : 18:00)
- prnewswire.com
GLAXF
|
News
|
$20.305
0.52%
-14.18%
0
|
Health Technology
|
5.21%
|
O:
5.68%
H:
0.77%
C:
0.77%
AZNCF
|
News
|
$138.73
1.86%
-4.19%
0
|
Health Technology
|
5.7%
|
O:
3.41%
H:
0.0%
C:
-2.45%
VTRS
|
News
A
|
$11.25
-0.13%
4.1M
|
Health Technology
|
-4.74%
|
O:
-0.08%
H:
3.47%
C:
-0.25%
NVS
|
News
|
$95.12
0.81%
4.36%
160K
|
Health Technology
|
-12.05%
|
O:
-2.04%
H:
0.19%
C:
-1.97%
GSK
|
News
|
$40.59
2.11%
0.1%
1.3K
|
Health Technology
|
3.84%
|
O:
4.04%
H:
1.57%
C:
-3.02%
ABBV
|
News
|
$167.89
0.89%
0.51%
3.6M
|
Health Technology
|
1.8%
|
O:
0.5%
H:
0.07%
C:
-0.81%
SNY
|
News
|
$47.15
1.84%
1.75%
2M
|
Health Technology
|
-7.95%
|
O:
1.75%
H:
0.0%
C:
0.0%
PBYI
|
$5.17
3.19%
3.09%
270K
|
Health Technology
|
8.5%
|
O:
-0.1%
H:
2.31%
C:
-1.26%
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
4.36%
|
O:
0.82%
H:
0.12%
C:
-1.64%
AMGN
|
News
|
$271.91
1.11%
1.12%
560
|
Health Technology
|
-13.58%
|
O:
0.44%
H:
0.2%
C:
-0.55%
drug
breast
expected
cancer
pipeline
therapeutics
growth
market
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Published:
2024-01-08
(Crawled : 12:00)
- prnewswire.com
CGEN
|
$2.03
3.57%
3.45%
450K
|
Health Technology
|
30.86%
|
O:
2.29%
H:
8.38%
C:
4.47%
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
2.56%
|
O:
0.28%
H:
0.99%
C:
0.93%
first
million
payment
astrazeneca
cancer
trial
milestone
Cancer Immunotherapy Market to grow by USD 38.57 billion from 2022 to 2027, North America to account for 41% of market growth- Technavio
Published:
2024-01-04
(Crawled : 23:00)
- prnewswire.com
GLAXF
|
News
|
$20.305
0.52%
-14.18%
0
|
Health Technology
|
4.0%
|
O:
2.46%
H:
0.0%
C:
0.0%
SNYNF
|
News
|
$92.7
-2.18%
77
|
Health Technology
|
-8.98%
|
O:
0.49%
H:
0.6%
C:
-0.83%
AZNCF
|
News
|
$138.73
1.86%
-4.19%
0
|
Health Technology
|
1.23%
|
O:
0.15%
H:
1.88%
C:
-1.17%
NVSEF
|
News
|
$95.11
5.4%
6.88%
0
|
Health Technology
|
-9.42%
|
O:
-0.24%
H:
1.43%
C:
1.43%
NVS
|
News
|
$95.12
0.81%
4.36%
160K
|
Health Technology
|
-10.23%
|
O:
0.32%
H:
0.93%
C:
0.38%
GSK
|
News
|
$40.59
2.11%
0.1%
1.3K
|
Health Technology
|
3.89%
|
O:
-0.36%
H:
0.98%
C:
0.72%
SNY
|
News
|
$47.15
1.84%
1.75%
2M
|
Health Technology
|
-9.28%
|
O:
-0.14%
H:
0.0%
C:
0.0%
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
1.96%
|
O:
-0.68%
H:
0.87%
C:
0.1%
AMGN
|
News
|
$271.91
1.11%
1.12%
560
|
Health Technology
|
-10.31%
|
O:
-0.32%
H:
0.44%
C:
0.26%
america
cancer
immunotherapy
market
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Published:
2023-12-19
(Crawled : 12:30)
- prnewswire.com
CGEN
|
$2.03
3.57%
3.45%
450K
|
Health Technology
|
213.7%
|
O:
178.08%
H:
21.18%
C:
-1.48%
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
6.34%
|
O:
-0.5%
H:
0.99%
C:
0.43%
first
payment
astrazeneca
cancer
trial
milestone
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
Published:
2023-12-18
(Crawled : 00:00)
- biospace.com/
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
8.23%
|
O:
1.03%
H:
1.08%
C:
0.73%
breast
cancer
trials
plus
initiated
Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer
Published:
2023-12-06
(Crawled : 22:00)
- biospace.com/
ILMN
|
$120.25
2.4%
2.37%
2.2K
|
Health Technology
|
7.6%
|
O:
1.4%
H:
3.94%
C:
0.58%
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
9.56%
|
O:
0.73%
H:
0.06%
C:
-1.38%
america
lung
conference
test
cancer
Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028| AbbVie Inc., Amgen Inc., Arrien Pharmaceuticals LLC and more among the key companies in the market - Technavio
Published:
2023-12-05
(Crawled : 23:00)
- prnewswire.com
GLAXF
|
News
|
$20.305
0.52%
-14.18%
0
|
Health Technology
|
14.62%
|
O:
1.64%
H:
0.0%
C:
-1.33%
AZNCF
|
News
|
$138.73
1.86%
-4.19%
0
|
Health Technology
|
10.32%
|
O:
1.51%
H:
0.13%
C:
-1.68%
NVS
|
News
|
$95.12
0.81%
4.36%
160K
|
Health Technology
|
-2.27%
|
O:
0.52%
H:
0.18%
C:
-0.43%
GSK
|
News
|
$40.59
2.11%
0.1%
1.3K
|
Health Technology
|
11.73%
|
O:
-0.03%
H:
0.28%
C:
-0.41%
BAX
|
$40.4
2.36%
0.0%
2.7M
|
Health Technology
|
12.85%
|
O:
0.14%
H:
0.78%
C:
0.22%
ABBV
|
News
|
$167.89
0.89%
0.51%
3.6M
|
Health Technology
|
16.13%
|
O:
0.26%
H:
0.0%
C:
0.0%
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
9.56%
|
O:
0.73%
H:
0.06%
C:
-1.38%
AMGN
|
News
|
$271.91
1.11%
1.12%
560
|
Health Technology
|
0.38%
|
O:
0.2%
H:
0.2%
C:
-0.76%
GOOGL
|
News
S
|
$156.28
1.42%
1.41%
110K
|
Technology Services
|
21.15%
|
O:
1.97%
H:
0.0%
C:
0.0%
GOOG
|
News
S
|
$157.95
1.43%
1.42%
97K
|
Technology Services
|
21.16%
|
O:
1.97%
H:
0.0%
C:
0.0%
ADBE
A
|
$466.89
0.4%
0.4%
3.8K
|
Technology Services
|
-22.47%
|
O:
0.97%
H:
0.08%
C:
-2.03%
tube
companies
abbvie
cancer
pharmaceuticals
therapeutics
market
Laryngeal Cancer Therapeutics Market size to grow by USD 575.25 million from 2022-2027| Accord Healthcare Ltd., Amgen Inc., AstraZeneca Plc, Athenex Inc. and more among the major companies in the market- Technavio
Published:
2023-12-01
(Crawled : 23:00)
- prnewswire.com
SNY
|
News
|
$47.15
1.84%
1.75%
2M
|
Health Technology
|
Email alert
Add to watchlist
TEVJF
|
News
|
$12.37
-24.22%
380
|
Health Technology
|
Email alert
Add to watchlist
SNYNF
|
News
|
$92.7
-2.18%
77
|
Health Technology
|
Email alert
Add to watchlist
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
Email alert
Add to watchlist
AZNCF
|
News
|
$138.73
1.86%
-4.19%
0
|
Health Technology
|
Email alert
Add to watchlist
AMGN
|
News
|
$271.91
1.11%
1.12%
560
|
Health Technology
|
Email alert
Add to watchlist
companies
astrazeneca
cancer
therapeutics
market
Locally Advanced Pancreatic Cancer Market Report 2023-2028: Recent Advancements in Immunotherapy Inject New Hope into LAPC Market
Published:
2023-11-21
(Crawled : 23:00)
- prnewswire.com
AZNCF
|
News
|
$138.73
1.86%
-4.19%
0
|
Health Technology
|
10.42%
|
O:
0.76%
H:
0.0%
C:
-0.05%
BMY
|
$49.14
0.43%
0.2%
6.4M
|
Health Technology
|
1.36%
|
O:
0.56%
H:
1.53%
C:
1.37%
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
9.1%
|
O:
-0.89%
H:
0.33%
C:
-0.16%
report
hope
cancer
pancreatic
immunotherapy
market
Increasing Prevalence of Laryngeal Cancer Fuels Growth in Laryngeal Cancer Therapeutics Market
Published:
2023-10-27
(Crawled : 02:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
77
|
Health Technology
|
-11.93%
|
O:
-18.18%
H:
0.0%
C:
0.0%
AZNCF
|
News
|
$138.73
1.86%
-4.19%
0
|
Health Technology
|
10.74%
|
O:
-1.1%
H:
0.18%
C:
-1.98%
SNY
|
News
|
$47.15
1.84%
1.75%
2M
|
Health Technology
|
-12.92%
|
O:
-15.73%
H:
0.0%
C:
0.0%
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
10.6%
|
O:
-0.42%
H:
0.13%
C:
-1.99%
AMGN
|
News
|
$271.91
1.11%
1.12%
560
|
Health Technology
|
0.82%
|
O:
-0.28%
H:
0.15%
C:
-2.74%
cancer
therapeutics
growth
market
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
Published:
2023-10-23
(Crawled : 19:00)
- biospace.com/
AZN
|
News
|
$70.13
2.31%
2.24%
11K
|
Health Technology
|
9.87%
|
O:
-1.57%
H:
1.06%
C:
0.36%
breast
her2
cancer
trial
negative
← Previous
1
2
3
4
5
6
7
8
Next →
Gainers vs Losers
73%
27%
Top 10 Gainers
AGBA
|
$2.5
100.0%
58.33%
200M
|
Finance
EDBL
|
News
|
$6.26
66.49%
48.56%
270K
|
MLEC
|
$2.47
76.43%
38.05%
460K
|
n/a
SILO
|
$1.99
0.71%
20.64%
1.8M
|
Finance and Insurance
NNVC
|
$1.12
1.82%
19.64%
2.5K
|
Health Technology
CANG
|
$1.34
-4.29%
14.93%
120K
|
Technology Services
AZTR
4
|
$0.195
13.85%
42K
|
n/a
TOVX
|
News
|
$0.411
-1.01%
12.9%
230K
|
Manufacturing
IBRX
|
$4.94
-6.26%
10.83%
4.5M
|
Manufacturing
MSTR
M
|
$1324.01
12.77%
10.65%
26K
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.